Adeno-associated Virus Vectors for Targeted and Repeat Delivery

用于靶向和重复递送的腺相关病毒载体

基本信息

批准号：
7938903
负责人：
RICHARD J SAMULSKI
金额：
$ 33.67万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-01 至 2013-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7938903
关键词：
Address Affect Amino Acids Animal Model Biological Assay Biopsy Canis familiaris Capsid Child Clinic Clinical Clinical Trials Collaborations Collection DNA DNA Shuffling Disease Dose Duchenne muscular dystrophy Engineering Escape Mutant Gene Delivery Gene Transfer Generations Genes Genetic Genome Goals Heart Hereditary Disease Hot Spot Human Humoral Immunities Immune Immune response Immunohistochemistry Individual Intramuscular Laboratories Libraries Liver Manuscripts Maps Modeling Molecular Molecular Cloning Mus Muscle Muscular Dystrophies Myocardium Myopathy Parents Patients Phase Phase I Clinical Trials Preclinical Testing Reagent Recombinants Reporter Genes Research Research Design Safety Sampling Screening procedure Serotyping Serum Skeletal Muscle Steroids Structure Surface Technology Testing Therapeutic Tissues Translations Uncertainty Validation Vertebral column Viral Virus Virus Receptors adeno-associated viral vector base combinatorial common treatment design directed evolution gene replacement gene therapy gene therapy clinical trial improved intravenous administration mini-dystrophin mutant nonhuman primate novel particle pre-clinical preclinical efficacy skeletal success trafficking trait transduction efficiency transgene expression vector

项目摘要

Adeno-associated Virus Vectors for Targeted and Repeat Delivery Project 1 "Adeno-associated Virus Vectors for Targeted and Repeat Delivery" will capitalize on AAV vector results derived from the on-going AAV Phase I DMD clinical trial. The advent of novel AAV vectors (serotype 1-11) and the solving of the capsid crystal structure, has allowed us and others to carry out rational design of AAV capsids to generate laboratory strains of gene delivery vehicles. Using such an approach, we have been successful in engineering AAV type 2 liver tropic vectors into a muscle tropic virus using only 5 amino acids derived from AAV type 1 capsid backbone. This novel chimeric reagent (AAV 2.5) has a distinct immune profile when compared to capsid backbone of parent serotypes and has high efficiency for muscle transduction. Due to the advantages of this chimeric AAV particle we recently initiated a Phase I Gene Therapy clinical trial for DMD with Dr. Xiao. Early information derived from these efforts has provided hypothesis driven approaches to better understand basic steps such as immune response to viral capsid, viral /receptor interaction, intra-cellular trafficking, and transgene expression. In the proposed studies, we hope to capitalize on these observations by deriving a collection of disease tropic vectors with novel immune profile that will allow for repeat administration. These objectives will be carried out by availability to AAV DNA capsid library technology, selection against patient neutralizing serum (including on-going AAV clinical trial), and use of large animal models carrying muscle specific disease traits (Project 3). Our objective is to better understand the molecular mechanism of efficient vector muscle transduction that will allow these and other novel delivery reagents for skeletal and heart specific muscle gene therapy. Success of these studies will facilitate the immediate goals of Project 2 and the long-term objective of initiating clinical trial for muscle disorders.

靶向和重复输送的腺相关病毒向量项目1“针对目标和重复分娩的腺相关病毒向量”将利用AAV 载体结果来自正在进行的AAV I期DMD临床试验。小说AAV载体的出现（血清型1-11）和capsid晶体结构的解决，使我们和其他人能够进行理性 AAV Capsids的设计以产生基因输送车的实验室菌株。使用这种方法，我们仅使用5个源自AAV 1型衣壳主链的氨基酸。这个小说的嵌合试剂（AAV 2.5）具有独特的与母体血清型的衣壳骨架相比，免疫轮廓且对肌肉具有很高的效率转导。由于该嵌合AAV粒子的优势，我们最近启动了一个I期基因 DR博士的DMD治疗临床试验。这些努力提供了早期信息假设驱动的方法更好地理解基本步骤，例如对病毒capsid的免疫反应，病毒 /受体相互作用，细胞内运输和转基因表达。在拟议的研究中，我们希望通过得出具有新型免疫力的疾病热带向量来利用这些观察结果轮廓将允许重复给药。这些目标将通过对AAV DNA的可用性实现衣壳图书馆技术，针对患者中和血清的选择（包括正在进行的AAV临床试验），并使用具有肌肉特异性疾病特征的大型动物模型（项目3）。我们的目标是更好了解有效载体肌肉转导的分子机制，这将允许这些和其他用于骨骼和心脏特异性肌肉基因治疗的新型递送试剂。这些研究的成功将促进项目2的直接目标，并启动肌肉临床试验的长期目标疾病。